AAV NRF2基因疗法在动物氧化损伤模型中保护视网膜结构和功能
Apolonia Gardner1, Shuai Wang2, Adam Daniels2
1Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Program in Virology, Harvard Medical School, Boston, MA 02115, USA.
使用AAV8/Best1-NRF2的基因疗法在干燥的老年性黄斑变性模型中保护视力损失. 这种方法针对氧化应激,这是疾病的关键因素,为未来的治疗提供了潜力.
科学领域:
- 眼科医生 眼科 眼科
- 基因治疗 基因治疗
- 神经科学是一个神经科学.
背景情况:
- 与年龄相关的干性黄斑变性 (AMD) 是50岁以上成年人视力丧失的主要原因之一.
- 被吸烟等因素加剧的氧化压力对AMD的发病有显著的贡献.
- 目前对干性AMD的治疗方法有限,这凸显了对新型治疗策略的需求.
研究的目的:
- 评估AAV8/Best1-NRF2基因疗法的疗效,在临床前的干老年性黄斑变性模型中.
- 研究NRF2激活对视网膜细胞中氧化损伤的保护作用.
- 为了确定AAV8/Best1-NRF2是否可以在氧化应激诱导的视网膜损伤模型中保持视觉功能.
主要方法:
- 在老鼠和小鼠中利用酸盐诱导的氧化应激模型来模仿干燥的AMD.
- 给药的亚底内注射腺相关病毒载体血清型8携带人类NRF2 (AAV8/Best1-NRF2).
- 评估了视网膜色素表皮和光受体细胞的保护,以及视觉功能的保护.
主要成果:
- 通过AAV8/Best1-NRF2基因疗法,可显著保护视网膜色素上皮细胞和光受体.
- 与对照组相比,接受治疗的动物显示视觉功能得到保护.
- 该疗法有效地减轻了酸诱导的氧化损伤.
结论:
- AAV8 / Best1-NRF2基因疗法显示为干燥的与年龄相关的黄斑退行症的神经保护性治疗的前景.
- 通过基因疗法激活NRF2可能为治疗由氧化应激驱动的视网膜疾病提供一种基因无关的方法.
- 这项研究支持进一步调查AAV8/Best1-NRF2在AMD和其他与氧化应激相关的视力损伤中临床应用.
更多相关视频
09:20Isolation of Next-Generation Gene Therapy Vectors through Engineering, Barcoding, and Screening of Adeno-Associated Virus AAV Capsid Variants
Published on: October 18, 2022
21:55Engineering and Evolution of Synthetic Adeno-Associated Virus AAV Gene Therapy Vectors via DNA Family Shuffling
Published on: April 2, 2012
相关概念视频
Gene Therapy
Structural Protein Function
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity. In bones and teeth, it mineralizes to...
Structural Protein Function
Structure of a Gene
However, only 1% of the DNA is composed of genes that encode proteins; the rest, 99% is non-coding DNA. This non-coding DNA performs...
Fruit Development, Structure, and Function
Modeling in Therapy
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
